1. Home
  2. BALY vs AKBA Comparison

BALY vs AKBA Comparison

Compare BALY & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bally's Corporation

BALY

Bally's Corporation

HOLD

Current Price

$16.37

Market Cap

651.4M

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.60

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BALY
AKBA
Founded
2004
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
651.4M
729.1M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
BALY
AKBA
Price
$16.37
$1.60
Analyst Decision
Hold
Strong Buy
Analyst Count
5
6
Target Price
$15.40
$6.25
AVG Volume (30 Days)
131.7K
4.0M
Earning Date
11-10-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,490,807,000.00
$225,071,000.00
Revenue This Year
$5.78
$52.38
Revenue Next Year
$4.82
$22.45
P/E Ratio
N/A
N/A
Revenue Growth
0.36
32.49
52 Week Low
$8.46
$1.45
52 Week High
$22.41
$4.08

Technical Indicators

Market Signals
Indicator
BALY
AKBA
Relative Strength Index (RSI) 49.31 40.49
Support Level $14.72 $1.45
Resistance Level $17.80 $1.61
Average True Range (ATR) 1.29 0.08
MACD -0.18 0.05
Stochastic Oscillator 36.26 62.75

Price Performance

Historical Comparison
BALY
AKBA

About BALY Bally's Corporation

Ballys Corp is a gaming, hospitality, and entertainment company with a portfolio of casinos and resorts and a growing omnichannel presence. It provides customers with physical and interactive entertainment and gaming experiences, including traditional casino offerings, iGaming, online bingo, sportsbook, and free-to-play (F2P) games. The company owns and operates, several casinos across the United States, one golf course in New York, one horse racetrack in Colorado, and Aspers Casino in the United Kingdom. Its Interactive International division, an interactive gaming operator concentrated in Europe, operates a lottery management and services business. The company's reportable segments are Casinos and Resorts, which derive key revenue, International Interactive and North America Interactive.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: